We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+24.71%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.26B
AUM Growth
+$265M
Cap. Flow
+$44M
Cap. Flow %
3.5%
Top 10 Hldgs %
89.49%
Holding
23
New
5
Increased
5
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
+$22.9M
2
AERI
Aerie Pharmaceuticals
AERI
+$18.1M
3
STIM icon
Neuronetics
STIM
+$16M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$9.24M
5
FOLD
Amicus Therapeutics
FOLD
+$7.92M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$22.3M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$14.7M
3
MRUS
Merus
MRUS
+$6.53M
4
IVTY
Invuity, Inc
IVTY
+$740K

Sector Composition

Rank Sector Weight
1 Healthcare 94.03%
2 Financials 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
1
Inogen
INGN
$171M
$866M 68.79%
3,549,320
– –
GKOS icon
2
Glaukos
GKOS
$8.92B
$39.1M 3.11%
602,709
– –
CRVS icon
3
Corvus Pharmaceuticals
CRVS
$1.09B
$37.9M 3.01%
4,420,516
– –
XLRN
4
DELISTED
Acceleron Pharma
XLRN
$37.2M 2.95%
650,000
-453,937
-41% -$22.3M
AKBA icon
5
Akebia Therapeutics
AKBA
$343M
$27.4M 2.17%
3,100,000
– –
AERI
6
DELISTED
Aerie Pharmaceuticals
AERI
$25.1M 2%
408,562
+282,165
+223% +$18.1M
DERM
7
DELISTED
Dermira, Inc.
DERM
$24.5M 1.95%
1,993,746
– –
KIDS icon
8
OrthoPediatrics
KIDS
$509M
$24M 1.9%
654,549
+1,200
+0.2% +$36.8K
ETTX
9
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$23.7M 1.88%
+2,181,843
New +$22.9M
MRUS
10
DELISTED
Merus
MRUS
$21.8M 1.73%
1,102,795
-307,622
-22% -$6.53M
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
$19.9M 1.58%
1,647,870
+566,689
+52% +$7.92M
STIM icon
12
Neuronetics
STIM
$126M
$16.8M 1.34%
+525,000
New +$16M
SPNE
13
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$15.3M 1.21%
983,037
+55,249
+6% +$782K
VYNE icon
14
VYNE Therapeutics
VYNE
$19.1M
$14.1M 1.12%
399
– –
NBRV
15
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$12.7M 1.01%
18,815
+7,260
+63% +$5.15M
LKFT
16
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
$9.84M 0.78%
+87,481
New +$9.24M
VRNA
17
DELISTED
Verona Pharma
VRNA
$9.27M 0.74%
740,740
– –
IVTY
18
DELISTED
Invuity, Inc
IVTY
$8.95M 0.71%
1,209,854
-153,994
-11% -$740K
COGT icon
19
Cogent Biosciences
COGT
$6.91B
$6.85M 0.54%
166,295
– –
WMGIZ
20
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
– –
0
– –
CRNX icon
21
Crinetics Pharmaceuticals
CRNX
$8.87B
$4.3M 0.34%
+150,000
New +$4.45M
RARX
22
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$4.07M 0.32%
225,000
-1,240,838
-85% -$14.7M
C icon
23
Citigroup
C
$223B
$3.77M 0.3%
+52,500
New +$3.71M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q3 2018 Portfolio in Review

As of Q3 2018, Novo Holdings A/S held 23 positions worth $1.26B, up 27% from $995M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Novo Holdings A/S deployed $44M of net new capital in Q3 2018, opening 5 new positions and adding to 5 existing holdings. Its largest new stake was Entasis Therapeutics Holdings Inc.: 2,181,843 shares worth $23.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Acceleron Pharma, an estimated $22.3M trimmed.

  • Novo Holdings A/S's largest Q3 2018 buy was Entasis Therapeutics Holdings Inc.: 2,181,843 shares worth $23.7M.
  • Novo Holdings A/S added most to Aerie Pharmaceuticals in Q3 2018, an estimated $18.1M increase.
  • Novo Holdings A/S's biggest Q3 2018 reduction was Acceleron Pharma, cutting an estimated $22.3M.
  • Novo Holdings A/S's ten largest holdings make up 89% of its $1.26B portfolio in Q3 2018.
  • Novo Holdings A/S opened 5 new positions and closed 0 in Q3 2018.
  • Novo Holdings A/S's portfolio value rose 27% quarter-over-quarter to $1.26B.

Based on Novo Holdings A/S's 13F filing for Q3 2018, filed 14 Nov 2018.